Moberg Pharma publishes bond prospectus and applies for listing of its bond loan on Nasdaq Stockholm

STOCKHOLM, February 23rd 2016. Moberg Pharma AB (publ) (”Moberg Pharma” or ”the
company", OMX: MOB)  publishes a bond prospectus and applies for listing on
Nasdaq Stockholm of its bond loan.
On January 25th 2016, Moberg Pharma announced that the company has issued a
senior unsecured bond loan in the amount of SEK 300 million within a total
framework amount of SEK 600 million. The bond loan will mature on January 29th
2021 and carries an annual interest rate of STIBOR (3 months) + 6.00 percentage
points.

The company has applied for listing of the bon loan on Nasdaq Stockholm and the
first day of trading is expected to be on February 25th 2016. In view of the
listing, the company has prepared a prospectus that has been approved by the
Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The prospectus
is available on the company's website www.mobergpharma.se and on the Swedish
Financial Supervisory Authority’s website www.fi.se.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 14.00 am (CET) on February 23rd 2016.
For additional information contact:
Peter Wolpert, CEO, Telephone: +46 707 35 71 35, E-mail:
peter.wolpert@mobergpharma.se
Anna Ljung, CFO, Telephone: +46 707 66 60 30, E-mail: anna.ljung@mobergpharma.se
About Moberg Pharma AB (publ)
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
OTC sales operations in the U.S. and a distributor network in more than 40
countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal
Nail®, Balmex®, Domeboro®, Jointflex®, Vanquish®, and Fergon®. Kerasal
Nail®(Emtrix®or Nalox™ in certain markets) is a leading OTC treatment of nail
disorders in the U.S., Canada and several EU markets and is currently being
launched in Southeast Asia. The company is growing organically as well as
through acquisitions. Internal development programs focuses on innovative drug
delivery of proven compounds and include two phase II assets, MOB-015
(onychomycosis) and BUPI (oral mucositis). Moberg Pharma has offices in
Stockholm and New Jersey and the company’s shares are listed on the Small Cap
list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB). For further
information, please visit: www.mobergpharma.com.